Skip to main content
. Author manuscript; available in PMC: 2020 Oct 30.
Published in final edited form as: Leukemia. 2020 Jan 27;34(7):1816–1827. doi: 10.1038/s41375-020-0710-7

Figure 6.

Figure 6.

Romidepsin can restore genes dysregulated by p53 mutation by increase histone acetylation and preferentially targets TP53mut cells

(A) p21 and GADD45A gene expressions upon 24h Romidepsin treatment. #P<0.05 compare to parental cells. (B) ChIP for ac-H3 in OCI-AML2 R50 cells with or without Romidepsin treatment at p21 and GADD45A promoter region. (C) GSEA was performed based on RNA-seq data for Romidepsin treatment in OCI-AML2 R50 cells. Heatmap shows expression of p53 target genes in OCI-AML2, OCI-AML2 50R and OCI-AML2 50R Romidepsin treated cells. (D) Single cell clone of MV4–11 TP53wt cells and TP53mut labeled with GFP were mixed and treated with either vehicle or 1nM Romidepsin. Cells were tested by FACS analysis on day 4. Bars indicate the standard error of mean. *P < 0.05